Home  »  Companies   »  Gain Therapeutics Inc (GANX) Is Waiting On The Lau...

Gain Therapeutics Inc (GANX) Is Waiting On The Launchpad To Make A Splash.

Gain Therapeutics Inc (NASDAQ:GANX) concluded the trading at $5.04 Friday, February 09 with a rise of 4.13% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $4.84 and 5Y monthly beta was reading 0.39 . Considering stock’s 52-week price range provides that GANX hit a high price of $6.19 and saw its price falling to a low level of $2.00 during that period. Over a period of past 1-month, stock came adding 44.41% in its value.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

With its current market valuation of $103.12 million, Gain Therapeutics Inc is set to declare its quarterly results on Mar 21, 2024 – Mar 25, 2024. Analysts are in estimates of -$0.32 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$1.57 for 2023 with estimates of that growing to -$1.12 in next year. These estimates are suggesting current year growth of -6.10% for EPS and 28.70% growth next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $320k. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $310k in 2023, which will be 121.40% more from revenue generated by the company last year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review GANX stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of Hold. Long term indicators are suggesting an average of 50% Buy for it.

Digging deeper we become aware of the PEG ratio of the GANX stock which is currently positioned at 0. It further provides that stock’s current price level is 33.21% away from its 20-day simple moving average and is 57.88% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 77.99 while volatility remained at 13.93% over the past week which changes to 9.72% when measuring it over the past month. Beta is valued at 0.46, while measure of average true range or ATR is currently at 0.40.

Having a second look at Gain Therapeutics Inc (NASDAQ:GANX) provides that stock’s average daily trading volume for 3 months was 141.37K, while it jumped to 0.33 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 20.46 million.

The percentage of outstanding shares held by the insiders is 12.78% while it is 7.31% for the institutional holders. The figures also indicate that as of Jan 12, 2024, number of stock’s short shares was 0.1 million which implies a short ratio of 0.8. This shows down a 0.64% of Short Interest in company’s outstanding shares on the day. In January the standing of shares short improved as it was 0.11 million in the previous month. Addition of 54.36% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.